Guide des anticorps monoclonaux à usage thérapeutique
contenu
menu
navigation
outils
Infliximab
Infliximab (REMICADE®) - Bioréférent
Infliximab (FLIXABI®) - Biosimilaire
Infliximab (INFLECTRA®) - Biosimilaire
Infliximab (REMSIMA®) - Biosimilaire (iv) - Biobetter (sc)
Infliximab (ZESSLY®) - Biosimilaire
Précédent
Suivant
Objectifs
Accès Rapide
Nouveautés dans Acthera
Généralités sur les anticorps
Présentation par indications thérapeutiques
Les AcM à usage thérapeutique (liste alphabétique par DCI)
Abatacept (ORENCIA®)
Abciximab (REOPRO®)
Adalimumab
Aflibercept (ZALTRAP®, EYLEA®)
Alemtuzumab (LEMTRADA®)
Alirocumab (PRALUENT®)
Anakinra (KINERET®)
Anifrolumab (SAPHNELO®)
Atezolizumab (TECENTRIQ®)
Avelumab (BAVENCIO®)
Basiliximab (SIMULECT®)
Belantamab mafodotin (BLENREP®)
Belatacept (NULOJIX®)
Belimumab (BENLYSTA®)
Benralizumab (FASENRA®)
Besilesomab (SCINTIMUN®)
Bevacizumab
Bezlotoxumab (ZINPLAVA®)
Bimekizumab (BIMZELX®)
Blinatumomab (BLINCYTO®)
Brentuximab vedotin (ADCETRIS®)
Brodalumab (KYNTHEUM®)
Brolucizumab (BEOVU®)
Burosumab (CRYSVITA®)
Canakinumab (ILARIS®)
Caplacizumab (CABLIVI®)
Casirivimab imdevimab (RONAPREVE®)
Catumaxomab (REMOVAB®)
Cemiplimab (LIBTAYO®)
Certolizumab pegol (CIMZIA®)
Cetuximab (ERBITUX®)
Crizanlizumab (ADAKVEO®)
Daclizumab (ZINBRYTA®)
Daratumumab (DARZALEX®)
Denosumab (PROLIA®, XGEVA®)
Dinutuximab beta (QARZIBA®)
Dostarlimab (JEMPERLI®)
Dupilumab (DUPIXENT®)
Durvalumab (IMFINZI®)
Eculizumab (SOLIRIS®) - Bioréférent
Efgartigimod alfa (VYVGART®)
Elotuzumab (EMPLICITI®)
Elranatamab (ELREXFIO®)
Emicizumab (HEMLIBRA®)
Enfortumab vedotin (PADCEV®)
Epcoritamab (TEPKINLY®)
Eptinezumab (VYEPTI®)
Erenumab (AIMOVIG®)
Etanercept
Evinacumab (EVKEEZA®)
Evolocumab (REPATHA®)
Faricimab (VABYSMO®)
Fremanezumab (AJOVY®)
Galcanezumab (EMGALITY®)
Gemtuzumab ozogamicin (MYLOTARG®)
Glofitamab (COLUMVI®)
Golimumab (SIMPONI®)
Guselkumab (TREMFYA®)
Ibalizumab (TROGARZO®)
Ibritumomab tiuxétan (ZEVALIN®)
Idarucizumab (PRAXBIND®)
Inebilizumab (UPLIZNA®)
Infliximab
Infliximab (REMICADE®) - Bioréférent
Infliximab (FLIXABI®) - Biosimilaire
Infliximab (INFLECTRA®) - Biosimilaire
Infliximab (REMSIMA®) - Biosimilaire (iv) - Biobetter (sc)
Infliximab (ZESSLY®) - Biosimilaire
Inotuzumab ozogamicin (BESPONSA®)
Ipilimumab (YERVOY®)
Isatuximab (SARCLISA®)
Ixekizumab (TALTZ®)
Lanadélumab (TAKHZYRO®)
Lebrikizumab (EBGLYSS®)
Loncastuximab tesirine (ZYNLONTA®)
Luspatercept (REBLOZYL®)
Mepolizumab (NUCALA®)
Mirikizumab (OMVOH®)
Mogamulizumab (POTELIGEO®)
Mosunetuzumab (LUNSUMIO®)
Moxetumomab pasudotox (Lumoxiti®)
Natalizumab (TYSABRI®)
Necitumumab (PORTRAZZA®)
Nirsevimab (BEYFORTUS®)
Nivolumab (OPDIVO®)
Obiltoxaximab (NYXTHRACIS®)
Obinutuzumab (GAZYVARO®)
Ocrelizumab (OCREVUS®)
Ofatumumab (KESIMPTA®)
Olaratumab (LARTRUVO®)
Omalizumab (XOLAIR®)
Palivizumab (SYNAGIS®)
Panitumumab (VECTIBIX®)
Pembrolizumab (KEYTRUDA®)
Pertuzumab (PERJETA®)
Pertuzumab-trastuzumab (PHESGO®)
Polatuzumab vedotin (POLIVY®)
Ramucirumab (CYRAMZA®)
Ranibizumab
Ravulizumab (ULTOMIRIS®)
Regdanvimab (REGKIRONA®)
Relatlimab - nivolumab (OPDUALAG®)
Reslizumab (CINQAERO®)
Retifanlimab (ZYNYZ®)
Risankizumab (SKYRIZI®)
Rituximab
Romosozumab (EVENITY®)
Rozanolixizumab (RYSTIGGO®)
Sacituzumab govitecan (TRODELVY®)
Sarilumab (KEVZARA®)
Satralizumab (ENSPRYNG®)
Secukinumab (COSENTYX®)
Siltuximab (SYLVANT®)
Sotrovimab (XEVUDY®)
Spesolimab (SPEVIGO®)
Sutimlimab (ENJAYMO®)
Tafasitamab (MINJUVI®)
Talquetamab (TALVEY®)
Teclistamab (TECVAYLI®)
Tezepelumab (TEZSPIRE®)
Tildrakizumab (ILUMETRI®)
Tixagevimab cilgavimab (EVUSHELD®)
Tocilizumab
Tralokinumab (ADTRALZA®)
Trastuzumab
Trastuzumab deruxtecan (ENHERTU®)
Trastuzumab emtansine (KADCYLA®)
Tremelimumab (IMJUDO®)
Ublituximab (BRIUMVI®)
Ustekinumab (STELARA®)
Vedolizumab (ENTYVIO®)
Conjugués anticorps-médicament (antibody-drug conjugates, ADC)
Anticorps monoclonaux bispécifiques
Les biosimilaires
Les cibles des AcM
Les pathologies ciblées
AcM disponibles à l'officine
Ressources sur les anticorps monoclonaux thérapeutiques
Tester vos connaissances
Mentions légales et contributeurs
Accueil
Module
Outils